Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing

2024-9-8

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

2024-8-28

A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability

2024-8-27

Developability considerations for bispecific and multispecific antibodies

2024-8-27

Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry

2024-8-27

The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics

2024-8-24

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer

2024-8-8

Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

2024-7-31

Quantifying LAGA mutated mouse IgG2a monoclonal antibody with a rapid pepsin digestion enabled immunoaffinity LC/MS/MS assay

2024-7-30

Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo

2024-7-25

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers

2024-7-24

Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

2024-7-23

Modulation of the high concentration viscosity of IgG ₁ antibodies using clinically validated Fc mutations

2024-7-19

Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations

2024-7-10

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

2024-7-4

Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment

2024-7-2

The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras

2024-7-1

Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen

2024-6-20

Synthetic integrin antibodies discovered by yeast display reveal αV subunit pairing preferences with β subunits

2024-6-18

Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling

2024-6-10

Correction

2024-6-7

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1

2024-6-7

Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn

2024-6-7

Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery

2024-6-6

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies

2024-6-6

Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach

2024-5-14

Correction

2024-5-12

Antibody association in solution: cluster distributions and mechanisms

2024-4-26

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

2024-4-26

Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring

2024-4-23

Alternative splicing for tuneable expression of protein subunits at desired ratios

2024-4-22

Can antibodies be “vegan”? A guide through the maze of today’s antibody generation methods

2024-4-18

Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody

2024-4-18

Enrichment strategy and initial characterization of heterodimers enriched from a co-formulated cocktail of therapeutic antibodies against SARS-COV-2

2024-4-9

Correction

2024-3-28

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based <i>in silico</i> approaches

2024-3-28

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

2024-3-27

Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry

2024-3-27

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties

2024-3-25

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

2024-3-21

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces

2024-3-18

Do antibody CDR loops change conformation upon binding?

2024-3-13

Reduction of monoclonal antibody viscosity using interpretable machine learning

2024-3-12

A pivotal decade for bispecific antibodies?

2024-3-11

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

2024-3-6

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge

2024-3-6

Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies

2024-3-6

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

2024-3-5

Biparatopic antibodies: therapeutic applications and prospects

2024-3-4

Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies

2024-3-4